Cardiovascular disease

Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session

Retrieved on: 
Monday, April 4, 2022
Company, Risk, Medication, Plasma, Form 10-K, Vascular disease, Therapy, American College of Cardiology, Biopharmaceutical, Multimedia, Annual report, Judgement, Liver, SEC, Serum, Ionis Pharmaceuticals, Ageing, Cardiovascular disease, Hypercholesterolemia, RNA, Moyamoya disease, AstraZeneca, View, Week, Today, Safety, Stroke, Knowledge, Goal, American College, Nasdaq, COVID-19, LICA, LDL-C, IONS, AES, Blood, Patient, Medical imaging, Pharmaceutical industry, Dietary supplement, Generic drug, PCSK9, Ionis

CARLSBAD, Calif., April 4, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its partner, AstraZeneca, today announced positive data from the ETESIAN Phase 2b study of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with hypercholesterolemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). These data were presented at the American College of Cardiology's 71st Annual Scientific Session & Expo.  

Key Points: 
  • These data were presented at the American College of Cardiology's 71st Annual Scientific Session & Expo.
  • The ETESIAN Phase 2b study's objective was to assess the efficacy, safety and tolerability of ION449 in patients with high-risk hypercholesterolemia.
  • "Today, we are pleased to announce that ETESIAN Phase 2b for ION449 (AZD8233) demonstrated a clear dose-response for both PCSK9 and LDL-C levels.
  • ION449 (AZD8233) dosed once monthly via subcutaneous administration, is an investigational medicine that uses Ionis' advanced LIgand-Conjugated Antisense (LICA) technology platform.

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

Retrieved on: 
Sunday, April 3, 2022
Health, Genetics, Research, Cardiology, Science, Biotechnology, People, Risk, Journal, Therapy, Plasma, Liver, Research, Pathology, Hematologic disease, AstraZeneca, MD, Sirna, Fats, American College, Sirna Therapeutics, Nasdaq, Annual report, History, RNA, Cholesterol, Lipid, Apolipoprotein B, Moyamoya disease, LDL, Cleveland Clinic, Industry, Stroke, Heart, U.S. Securities and Exchange Commission, Gene, Aortic stenosis, DNA, EVP, Silence Therapeutics, LPA, Cardiovascular disease, APOLLO, Lipoprotein(a), RNA interference, Protein, Patient, Company, American Medical Association, Infarction, Degenerative disease, Private Securities Litigation Reform Act, Safety, Mallinckrodt, Blood, JAMA, Pharmaceutical industry, Propane, Dietary supplement, Vaccine, Silence, Lp-LpA2

High Lp(a) affects around 20% of the worlds population and is associated with a high risk of heart attack, stroke and aortic stenosis.

Key Points: 
  • High Lp(a) affects around 20% of the worlds population and is associated with a high risk of heart attack, stroke and aortic stenosis.
  • SLN360 is a siRNA that is designed to lower Lp(a) production by targeting messenger RNA transcribed from the LPA gene.
  • The phase 1 APOLLO trial evaluated SLN360 in 32 adults at five medical centers in the U.S., UK and Netherlands.
  • Silence plans to initiate the SLN360 phase 2 ASCVD study in the second half of 2022, pending regulatory discussions.

Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)

Retrieved on: 
Saturday, April 2, 2022
Chronic kidney disease, Disease, Metabolism, ACC, Form 10-K, SGLT2, The New England Journal of Medicine, AHA, Diabetes, Clinical trial, Kidney, Patient, Annual report, Stroke, CVD, SGLT1, Hospital, American Heart Association, Cardiovascular disease, Medicine, Death, U.S. Securities and Exchange Commission, Type 2 diabetes, American College, Nasdaq, Gastrointestinal tract, Harvard Medical School, Intellectual property, Myocardial infarction, Gene, GLOBE, Heart failure, Neuropathic pain, EGFR, MACE, Protein, NEJM, Security (finance), Pharmaceutical industry, Brigham, Lexicon

The SCORED clinical trial randomized 10,584 patients with type 2 diabetes and chronic kidney disease to sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, or placebo.

Key Points: 
  • The SCORED clinical trial randomized 10,584 patients with type 2 diabetes and chronic kidney disease to sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, or placebo.
  • This analysis also evaluated the effect of sotagliflozin on MACE in prespecified subgroups of patients with cardiovascular disease (CVD; n=5,144) and without CVD (n=5,440) at baseline.
  • The lower rates of MACE, notably including reductions in both heart attack and stroke, were consistent in patients with and without cardiovascular disease at baseline.
  • We remain focused on our goal of making sotagliflozin available for the millions of people suffering from heart failure.

Cardiol Therapeutics Announces Year-End 2021 Update on Operations

Retrieved on: 
Thursday, March 24, 2022
People, Risk, Therapy, Biomarker, Management, Vaccine, Research, Biotechnology, Amgen, Goal, Cardiology, Dysrhythmia, Nasdaq, Pericarditis, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, Fibrosis, Houston, Heart failure, History, Disease, Heart, Cornell University, Diagnosis, Analysis, SEDAR, Myocarditis, Health, Quality of life, Industry, Weill Cornell Medicine, Houston Methodist Hospital, Pulmonary embolism, Phase, Hospital, Cancer, NASDAQ, Financial statement, Death, Infarction, Board, CMO, CVD, Cardiovascular disease, Conversation, Board of directors, Inflammation, Awareness, FDA, Patient, Company, CRDL, Cannabidiol, IND, Food, TSX, Safety, Stroke, Degenerative disease, News, Infection, Pharmaceutical industry, Medicine

David Elsley, President and Chief Executive Officer of Cardiol Therapeutics, commented: "In 2021 Cardiol Therapeutics accomplished several important goals.

Key Points: 
  • David Elsley, President and Chief Executive Officer of Cardiol Therapeutics, commented: "In 2021 Cardiol Therapeutics accomplished several important goals.
  • Dr. Hamer leads the research and development of Cardiol's clinical-stage products and guides the development of additional novel therapeutics in the Company's pipeline.
  • In April, Cardiol released topline results from a Phase I single and multiple ascending dose clinical trial of CardiolRx.
  • Raised $98 million in gross proceeds from financings completed during 2021, ending the year with cash and cash equivalents of $83.9M.

Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit

Retrieved on: 
Tuesday, March 22, 2022
Hospital, Company, Therapy, CRDL, Biomarker, Heart, NASDAQ, Myocarditis, Risk, Death, Cannabidiol, IND, CVD, Research, EDT, Cardiovascular disease, History, Cantor Fitzgerald, TSX, Safety, Inflammation, COVID-19, Degenerative disease, Fibrosis, News, FDA, Heart failure, Patient, Pharmaceutical industry

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-fibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease ("CVD").

Key Points: 
  • Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-fibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease ("CVD").
  • The Company's lead product candidate, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is being clinically developed for use in cardiovascular medicine.
  • CardiolRx is currently being evaluated in a Phase II/III multi-national, randomized, double-blind, placebo-controlled study (the LANCER trial).
  • These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information.

Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering

Retrieved on: 
Friday, April 1, 2022
Therapy, Obesity, Oppenheimer, Orphan, Body composition, NASDAQ, Degenerative disease, Sale, Form, Attention, Mortality, Caregiver, Public expenditure, Tablet, Research, SEC, Intellectual disability, Polyphagia, Cardiovascular disease, Telephone, Puberty, Medicine, Diazoxide, Behavioral Problems, Growth hormone, Prospectus, Quality of life, Diabetes, PWS, Perforated ulcer, Choking, Securities Exchange Act of 1934, Prader–Willi syndrome, GLOBE, NDA, FDA, Patient, SEC filing, Security (finance), Pharmaceutical industry, EU

Oppenheimer & Co. Inc.acted as the sole book-running manager for the offering.Laidlaw & Company (UK) Ltd. acted as co-manager for the offering.

Key Points: 
  • Oppenheimer & Co. Inc.acted as the sole book-running manager for the offering.Laidlaw & Company (UK) Ltd. acted as co-manager for the offering.
  • The offering was conducted pursuant to the Companys shelf registration statement on Form S-3 (File No.
  • Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.
  • Soleno conceived of and established extensive patent protection on the therapeutic use of diazoxide and DCCR in patients with PWS.

In Response to a New Study Revealing Approaching Diabetes Epidemic Among American Children, National Physicians Group Provides Roadmap to Curb Crisis, Improve Health of Young People

Retrieved on: 
Friday, April 1, 2022
Food, Beverage, Retail, Teens, Parenting, White House, Federal Government, Research, Children, State, Local, Other Policy Issues, Family, Consumer, Science, Public Policy, Government, General Health, Diabetes, Health, Healthcare Reform, Primary, Secondary, Education, People, USDA, Young People, Risk, Cholesterol, George Washington University School of Medicine & Health Sciences, Exercise, Fortis Healthcare, JAMA Pediatrics, Obesity, IMCL, Letter, Whole body vibration, Physicians Committee for Responsible Medicine, National Health, Ethics, National Health and Nutrition Examination Survey, Prediabetes, Pediatrics, Research, Meat, Ageing, FACC, Cancer, Cardiovascular disease, School, NHANES, Diabetes, Committee, Dairy, HCL, Vegetable, Degenerative disease, Education, Dietary supplement, Pharmaceutical industry, Medicine, MD

According to data from the U.S. governments National Health and Nutrition Examination Survey (NHANES) from 1999-2018, 1 in 5 children has prediabetes.

Key Points: 
  • According to data from the U.S. governments National Health and Nutrition Examination Survey (NHANES) from 1999-2018, 1 in 5 children has prediabetes.
  • To curb this crisis, the Physicians Committee, a nonprofit group of 17,000 doctors, outlined key steps to correct this approaching health epidemic.
  • Physicians Committee medical staff are prepared to assist in implementing the following strategy, which is a solid start to a response commensurate with the crisis at hand.
  • The Physicians Committee Roadmap to Address the Prediabetes Crisis Among Young People in the U.S.:
    Put in place vegan meals in U.S. public schools.

MUD\WTR Launches :rest, a Caffeine-Free Blend for a Relaxing Evening Ritual

Retrieved on: 
Friday, April 1, 2022
Bass, Life, Fungus, Obesity, Population, Human, Cacao, Digestion, Edible mushroom, Journalism, Research, Sleep, Cardiovascular disease, CEO, Health, Chamomile, Immunity, Coffee, Meditation, Safety, Caffeine, Diabetes, Time, Lists of diseases, Taste, Rest, MD

VENICE, Calif., April 01, 2022 /PRNewswire-PRWeb/ -- MUD\WTR's latest product delivers a profound message: "permission to rest." Research shows that how one rests, relax, and recover supports how one rises, create and performs the next day. The "snooze and lose" mantra touted by hustle culture has led us down a path of poor sleep, diminishing our well-being. With that in mind, Venice, CA-based MUD\WTR created :rest, a caffeine-free evening blend to promote a state of calm. It's formulated to give drinkers the type of sleep that makes them want to give their pillows a high-five the next day.

Key Points: 
  • The "snooze and lose" mantra touted by hustle culture has led us down a path of poor sleep, diminishing our well-being.
  • With that in mind, Venice, CA-based MUD\WTR created :rest , a caffeine-free evening blend to promote a state of calm.
  • It's formulated to give drinkers the type of sleep that makes them want to give their pillows a high-five the next day.
  • It's a reminder to treat your evening ritual like an athlete warming up for a game.

Allegheny Health Network Raises Awareness for Organ Donation during National Donate Life Month

Retrieved on: 
Friday, April 1, 2022
National Association Medical Staff Services, Donate Life America, Fifth Avenue Place, Life, Western Pennsylvania Hospital, Lake Erie College of Osteopathic Medicine, Heart, Saint Vincent Hospital, Allegheny General Hospital, Canonsburg Hospital, Drexel University College of Medicine, Network, Neurology, Lake Erie College, Kidney, Caregiver, James Forbes (hospital inspector), Culture, Liver, Allegheny Health Network, Jefferson Health, Research, Heal, Hospital, Cardiovascular disease, Neurosurgery, Death, Health, CEO, Tissue, AHN, OPOS, Center, Cornea, Diabetes, COVID-19, Transplant, Physician, Osteopathic medicine in the United States, Awareness, CORE, Patient, Pharmaceutical industry, Dentistry, Communications satellite, Janitor

PITTSBURGH, April 1, 2022 /PRNewswire-PRWeb/ -- April is National Donate Life Month, a special time of year when people come together to raise awareness for organ, tissue and cornea donations. This year, Allegheny Health Network (AHN) is hosting 'Donate Life Month' celebrations across 10 of its hospitals including Allegheny General, Allegheny Valley, Canonsburg, Forbes, Grove City, Jefferson, Saint Vincent, West Penn, Wexford and Hempfield. In part, the events intend to inform staff, patients and visitors about the critical importance of organ donation and how to become a registered organ donor.

Key Points: 
  • In observance of National Donate Life Month, Allegheny Health Network will host events at several of its hospitals throughout the month of April to help drive awareness about the importance of organ donation.
  • PITTSBURGH, April 1, 2022 /PRNewswire-PRWeb/ -- April is National Donate Life Month, a special time of year when people come together to raise awareness for organ, tissue and cornea donations.
  • This year, Allegheny Health Network (AHN) is hosting 'Donate Life Month' celebrations across 10 of its hospitals including Allegheny General, Allegheny Valley, Canonsburg, Forbes, Grove City, Jefferson, Saint Vincent, West Penn, Wexford and Hempfield.
  • "Allegheny Health Network is committed to raising awareness of organ donation and registration to bring more lifesaving transplants to the individuals who need it most.

Kindstar Globalgene Announces FY2021 Annual Results, Revenue Increases to RMB930.67 Million

Retrieved on: 
Friday, March 25, 2022
The Group, Company, Leukemia, Alzheimer's disease, Biomarker, Rheumatology, Hematology, Population, Degenerative disease, Group, Diagnosis, Neurology, JAK2, Immunotherapy, Infarction, IVD, Growth, Public health, Board, Cancer, Motherboard, Myasthenia, Cardiovascular disease, Hospital, Main Board for Serb Liberation, Moyamoya disease, Ophthalmology, NMPA, Medicine, Laboratory, Antiphospholipid syndrome, Industry, Review, Rheumatoid arthritis, Lists of diseases, Liver cancer, Cervical cancer, Ageing, COVID-19, Ankylosing spondylitis, Gout, CRO, Physician, Infection, Bladder cancer, R, Awareness, Empowerment, Patient, Disease, Hong Kong Stock Exchange, Pharmaceutical industry, Animal, Dietary supplement, Fine chemical, Vaccine

During the period under review, the Group recorded total revenue of RMB930.67 million, representing a year-on-year increase of 4.4%.

Key Points: 
  • During the period under review, the Group recorded total revenue of RMB930.67 million, representing a year-on-year increase of 4.4%.
  • During the period, the Group achieved revenue of RMB535.27 million and segment results of RMB152.57 million, representing a year-on-year increase of 14% and 15.7%, respectively.
  • The Group recorded revenue of RMB89.85 million and segment results of RMB14.06 million during the period, a year-on-year increase of 18.2 and 11.6%, respectively.
  • Kindstar Globalgene 2021 Annual Results Announcement:
    Infographics for Kindstar Globalgene 2021 Annual Results Announcement:
    Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Group"; stock code: 9960.HK) is a leading independent esoteric clinical testing service provider and a major provider of hematology esoteric testing services in China.